Loading...
XSHE300406
Market cap1.04bUSD
Jan 14, Last price  
12.95CNY
1D
3.27%
1Q
-1.52%
Jan 2017
-41.11%
IPO
128.40%
Name

Beijing Strong Biotechnologies Inc

Chart & Performance

D1W1MN
XSHE:300406 chart
P/E
14.55
P/S
4.37
EPS
0.89
Div Yield, %
0.77%
Shrs. gr., 5y
2.44%
Rev. gr., 5y
17.60%
Revenues
1.74b
+15.27%
275,963,544380,144,035444,625,403508,274,279566,201,720667,402,749694,277,363774,178,200840,861,681848,118,4931,599,384,3521,510,871,8841,741,626,675
Net income
524m
+34.60%
100,782,568137,009,922180,637,381210,640,919245,043,364271,646,051273,151,407300,665,281331,648,680112,277,109405,651,172389,097,640523,742,821
CFO
590m
+48.97%
45,898,334125,486,142147,193,672156,938,955142,586,445243,206,450207,907,483256,147,805188,603,373123,058,597341,098,641396,165,883590,149,292
Dividend
May 07, 20240.2 CNY/sh

Profile

Beijing Strong Biotechnologies, Inc. provides in-vitro diagnostics products and services in the People's Republic of China and internationally. It offers clinical biochemistry products, such as reagents and automatic biochemistry analyzers; coagulation products, including reagents and automated coagulation analyzers; and serology products comprising blood type test cards and automated blood grouping analyzers. The company was founded in 2001 and is headquartered in Beijing, the People's Republic of China.
URL
http://www.bsbe.com.cn/
IPO date
Oct 30, 2014
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,741,627
15.27%
1,510,872
-5.53%
Cost of revenue
890,874
900,843
Unusual Expense (Income)
NOPBT
850,753
610,029
NOPBT Margin
48.85%
40.38%
Operating Taxes
71,485
54,859
Tax Rate
8.40%
8.99%
NOPAT
779,268
555,171
Net income
523,743
34.60%
389,098
-4.08%
Dividends
(58,598)
(58,814)
Dividend yield
0.52%
0.61%
Proceeds from repurchase of equity
(49,451)
(51,105)
BB yield
0.44%
0.53%
Debt
Debt current
84,800
Long-term debt
1,136,574
1,018,744
Deferred revenue
18,650
Other long-term liabilities
16,974
1
Net debt
412,536
714,687
Cash flow
Cash from operating activities
590,149
396,166
CAPEX
(148,032)
Cash from investing activities
(132,271)
Cash from financing activities
(74,757)
FCF
825,471
77,777
Balance
Cash
724,038
340,720
Long term investments
2
48,137
Excess cash
636,956
313,313
Stockholders' equity
3,150,721
2,981,299
Invested Capital
4,233,228
4,041,694
ROIC
18.83%
14.43%
ROCE
17.44%
13.98%
EV
Common stock shares outstanding
595,162
588,842
Price
19.10
16.68%
16.37
-17.41%
Market cap
11,367,600
17.93%
9,639,343
-17.27%
EV
11,777,094
10,354,030
EBITDA
906,959
664,845
EV/EBITDA
12.99
15.57
Interest
46,992
52,642
Interest/NOPBT
5.52%
8.63%